BRPI0416950A8 - métodos para remover vírus de uma composição do fator vii líquida, para inativar vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquida - Google Patents
métodos para remover vírus de uma composição do fator vii líquida, para inativar vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquidaInfo
- Publication number
- BRPI0416950A8 BRPI0416950A8 BRPI0416950A BRPI0416950A BRPI0416950A8 BR PI0416950 A8 BRPI0416950 A8 BR PI0416950A8 BR PI0416950 A BRPI0416950 A BR PI0416950A BR PI0416950 A BRPI0416950 A BR PI0416950A BR PI0416950 A8 BRPI0416950 A8 BR PI0416950A8
- Authority
- BR
- Brazil
- Prior art keywords
- factor vii
- viruses
- vii composition
- liquid factor
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13061—Methods of inactivation or attenuation
- C12N2740/13063—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Water Supply & Treatment (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
"métodos para remover vírus de uma composição do fator vii líquida, para inativar. vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquida". a presente invenção diz respeito a um novo método para melhorar a segurança viral de composições de fator vii líquidas, em particular aquelas que compreendem polipeptídeos do fator vii ativos (um polipeptídeo do fator vila).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200301775 | 2003-12-01 | ||
| DKPA200301775 | 2003-12-01 | ||
| PCT/EP2004/053206 WO2005054275A2 (en) | 2003-12-01 | 2004-12-01 | Nanofiltration of factor vii solutions to remove virus |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0416950A BRPI0416950A (pt) | 2007-02-13 |
| BRPI0416950A8 true BRPI0416950A8 (pt) | 2019-01-22 |
| BRPI0416950B1 BRPI0416950B1 (pt) | 2019-05-28 |
| BRPI0416950B8 BRPI0416950B8 (pt) | 2021-05-25 |
Family
ID=34639198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0416950A BRPI0416950B8 (pt) | 2003-12-01 | 2004-12-01 | métodos para remover vírus de uma composição do fator vii líquida, para inativar vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquida. |
Country Status (14)
| Country | Link |
|---|---|
| US (8) | US20070142625A1 (pt) |
| EP (3) | EP1711513B1 (pt) |
| JP (3) | JP4874806B2 (pt) |
| KR (1) | KR101234170B1 (pt) |
| CN (3) | CN102351953B (pt) |
| AU (1) | AU2004294403A1 (pt) |
| BR (1) | BRPI0416950B8 (pt) |
| CA (1) | CA2545474A1 (pt) |
| DK (1) | DK1711513T3 (pt) |
| ES (2) | ES2926359T3 (pt) |
| PL (1) | PL1711513T3 (pt) |
| PT (1) | PT1711513E (pt) |
| RU (1) | RU2472804C2 (pt) |
| WO (1) | WO2005054275A2 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0416950B8 (pt) * | 2003-12-01 | 2021-05-25 | Novo Nordisk Healthcare Ag | métodos para remover vírus de uma composição do fator vii líquida, para inativar vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquida. |
| DE102005037824A1 (de) * | 2005-08-08 | 2007-02-15 | Zlb Behring Gmbh | Neuartiges Virusreduktionsverfahren |
| CN112076330B (zh) | 2010-12-30 | 2023-06-02 | 法国化学与生物科技实验室 | 作为病原体灭活剂的二元醇 |
| CN103582700B (zh) | 2011-03-25 | 2016-08-17 | 弗·哈夫曼一拉罗切有限公司 | 新的蛋白质纯化方法 |
| IN2014DN10441A (pt) | 2012-06-21 | 2015-08-21 | Baxter Int | |
| TWI641382B (zh) * | 2013-01-31 | 2018-11-21 | 韓美藥品股份有限公司 | 於包含因子ｖｉｉ之組成物中使病毒失活之方法 |
| RU2526494C1 (ru) * | 2013-03-19 | 2014-08-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения Российской Федерации" (ГБОУ ВПО ЧелГМА Минздрава России) | Способ удаления вируса иммунодефицита человека из спермы мужчины |
| KR102238133B1 (ko) * | 2013-11-15 | 2021-04-09 | 제넨테크, 인크. | 환경-친화적 세제를 사용한 바이러스 불활성화 방법 |
| CN105435644A (zh) * | 2014-09-29 | 2016-03-30 | 中国石油化工股份有限公司 | 一种纳滤膜及其制备方法 |
| WO2021030787A1 (en) | 2019-08-15 | 2021-02-18 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
| EP4189064A1 (en) * | 2020-07-30 | 2023-06-07 | Amgen Inc. | Cell culture media and methods of making and using the same |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3100501A (en) | 1960-12-23 | 1963-08-13 | Crane Co | Removable head and seat ball valve construction |
| JPS6033009B2 (ja) * | 1978-12-29 | 1985-07-31 | 三菱電機株式会社 | マイクロ波発振装置 |
| US4456591A (en) | 1981-06-25 | 1984-06-26 | Baxter Travenol Laboratories, Inc. | Therapeutic method for activating factor VII |
| US4540573A (en) * | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US5580560A (en) | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| US5997864A (en) | 1995-06-07 | 1999-12-07 | Novo Nordisk A/S | Modified factor VII |
| DE69233398D1 (de) | 1991-02-28 | 2004-09-16 | Novo Nordisk As | Modifizierter faktor-vii |
| DE4142908C2 (de) * | 1991-12-24 | 1994-02-10 | Octapharma Ag Glarus | Verfahren zur Herstellung eines virusinaktivierten Prothrombinkomplex-Konzentrats (PPSB) |
| DK38293D0 (da) | 1993-03-31 | 1993-03-31 | Novo Nordisk As | Fremstilling af proteiner |
| SE9500724D0 (sv) | 1994-06-23 | 1995-02-24 | Pharmacia Ab | Filtrering |
| US5677162A (en) * | 1995-05-01 | 1997-10-14 | New York Blood Center, Inc. | Method for activating prothrombin to thrombin |
| AT406019B (de) * | 1995-05-08 | 2000-01-25 | Immuno Ag | Verfahren zur herstellung eines arzneimittels enthaltend ein oder mehrere plasmaderivate |
| EP0860444A1 (en) * | 1997-02-24 | 1998-08-26 | Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) | Method for removing viruses from a protein solution |
| AT405608B (de) * | 1997-04-08 | 1999-10-25 | Immuno Ag | Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material |
| AT407159B (de) * | 1997-06-13 | 2001-01-25 | Immuno Ag | Verfahren zur abreicherung von viralen und molekularen pathogenen aus einem biologischen material |
| AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
| ATA159597A (de) * | 1997-09-19 | 2000-09-15 | Immuno Ag | Präparat zur behandlung von blutgerinnungsstörungen |
| US6017882A (en) | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6693075B1 (en) | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US5981254A (en) | 1997-10-30 | 1999-11-09 | Haemacure Corporation | Process for producing thrombin from plasma |
| KR20010031785A (ko) | 1997-11-05 | 2001-04-16 | 가마꾸라 아끼오 | 헤파린 보조인자 ｉｉ 제제 및 그 제조 방법 |
| FI106465B (fi) | 1998-06-10 | 2001-02-15 | Suomen Punainen Risti Veripalv | Menetelmä virusturvallisten farmaseuttisten koostumusten valmistamiseksi |
| AT408613B (de) | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
| EP1198565A1 (en) | 1999-07-07 | 2002-04-24 | Maxygen Aps | A method for preparing modified polypeptides |
| JP4451514B2 (ja) | 1999-08-24 | 2010-04-14 | 財団法人化学及血清療法研究所 | 血液凝固第ｖｉｉ因子改変体 |
| AU783512B2 (en) | 2000-02-11 | 2005-11-03 | Bayer Healthcare Llc | Factor VII or VIIa-like molecules |
| DE60143292D1 (de) | 2000-05-03 | 2010-12-02 | Novo Nordisk Healthcare Ag | Varianten des menschlichen Koagulationsfaktors VII |
| DE10022092A1 (de) | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| EP2253703A1 (en) | 2000-09-13 | 2010-11-24 | Novo Nordisk Health Care AG | Human coagulation factor VII variants |
| KR100880624B1 (ko) | 2000-10-02 | 2009-01-30 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 비타민 ｋ-의존 단백질의 생산 방법 |
| AU2002218029A1 (en) | 2000-11-09 | 2002-05-21 | The Scripps Research Institute | Modified factor viia |
| IL157842A0 (en) | 2001-03-22 | 2004-03-28 | Novo Nordisk Healthcare Ag | Coagulation factor vii derivatives |
| EP1432794B1 (en) | 2001-09-27 | 2011-11-09 | Novo Nordisk Health Care AG | Human coagulation factor vii polypeptides |
| CN102180944A (zh) | 2001-10-10 | 2011-09-14 | 诺和诺德公司 | 肽的重构和糖缀合 |
| US7265085B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
| US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
| ES2490590T3 (es) | 2001-11-02 | 2014-09-04 | Novo Nordisk Health Care Ag | Polipéptidos de factor VII de coagulación humana |
| DE10211632A1 (de) | 2002-03-15 | 2003-10-09 | Aventis Behring Gmbh | Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration |
| US20050131005A1 (en) | 2002-04-30 | 2005-06-16 | Jiabing Wang | 4-azasteroid derivatives as androgen receptor modulators |
| ATE488581T1 (de) | 2002-04-30 | 2010-12-15 | Bayer Healthcare Llc | Faktor vii oder faktor viia polypeptidvarianten |
| DE50311422D1 (de) | 2002-07-23 | 2009-05-28 | Bio & Bio Licensing Sa | Thrombingenerierfähige und thrombinhaltige pharmazeutische wirkstoffzubereitungen und arzneimittel |
| RS20050051A (en) | 2002-07-23 | 2007-06-04 | Bio-Products & Bio Engineering Ag., | Pharmaceutical active ingredient preparation and medicaments that contain thrombin or have a thrombin-generating capacity |
| CA2502162C (en) | 2002-09-30 | 2014-04-15 | Maxygen Holdings Ltd. | Fvii or fviia variants having increased clotting activity |
| WO2005002615A1 (en) * | 2003-07-01 | 2005-01-13 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
| BRPI0416950B8 (pt) | 2003-12-01 | 2021-05-25 | Novo Nordisk Healthcare Ag | métodos para remover vírus de uma composição do fator vii líquida, para inativar vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquida. |
| FR2901707B1 (fr) | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis |
| FR2901796A1 (fr) | 2006-05-31 | 2007-12-07 | Lab Francais Du Fractionnement | Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait |
| FR2904558B1 (fr) | 2006-08-01 | 2008-10-17 | Lab Francais Du Fractionnement | "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees" |
| FR2910786B1 (fr) | 2006-12-29 | 2017-08-11 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) | "procede d'extraction d'une proteine presente dans du lait" |
| FR2947181B1 (fr) | 2009-06-26 | 2012-05-04 | Lfb Biotechnologies | Composition de facteur vii |
| EP2687595B1 (en) | 2012-07-19 | 2018-05-30 | Laboratoire Français du Fractionnement et des Biotechnologies | Method for purifying transgenic factor VII |
-
2004
- 2004-12-01 BR BRPI0416950A patent/BRPI0416950B8/pt active IP Right Grant
- 2004-12-01 PT PT48046353T patent/PT1711513E/pt unknown
- 2004-12-01 KR KR1020067010639A patent/KR101234170B1/ko active IP Right Grant
- 2004-12-01 AU AU2004294403A patent/AU2004294403A1/en not_active Abandoned
- 2004-12-01 EP EP20040804635 patent/EP1711513B1/en not_active Revoked
- 2004-12-01 ES ES19186952T patent/ES2926359T3/es active Active
- 2004-12-01 PL PL04804635T patent/PL1711513T3/pl unknown
- 2004-12-01 CA CA002545474A patent/CA2545474A1/en not_active Abandoned
- 2004-12-01 CN CN201110303815.3A patent/CN102351953B/zh active Active
- 2004-12-01 EP EP10181049A patent/EP2275432A1/en not_active Ceased
- 2004-12-01 EP EP19186952.8A patent/EP3594222B1/en active Active
- 2004-12-01 CN CN201710263718.3A patent/CN106916802B/zh active Active
- 2004-12-01 RU RU2006118024/10A patent/RU2472804C2/ru active
- 2004-12-01 JP JP2006541943A patent/JP4874806B2/ja active Active
- 2004-12-01 WO PCT/EP2004/053206 patent/WO2005054275A2/en active Application Filing
- 2004-12-01 ES ES04804635.3T patent/ES2507091T3/es active Active
- 2004-12-01 CN CNA2004800357085A patent/CN1890257A/zh active Pending
- 2004-12-01 DK DK04804635.3T patent/DK1711513T3/da active
-
2006
- 2006-05-23 US US11/439,828 patent/US20070142625A1/en not_active Abandoned
-
2008
- 2008-07-15 US US12/173,475 patent/US20080274534A1/en not_active Abandoned
-
2011
- 2011-03-28 JP JP2011069695A patent/JP5666359B2/ja active Active
- 2011-08-18 JP JP2011178873A patent/JP2012021007A/ja not_active Withdrawn
-
2012
- 2012-01-13 US US13/349,980 patent/US9102762B2/en active Active
-
2015
- 2015-06-29 US US14/753,551 patent/US20150299685A1/en not_active Abandoned
-
2016
- 2016-10-05 US US15/286,068 patent/US20170022482A1/en not_active Abandoned
-
2018
- 2018-09-28 US US16/145,565 patent/US20190032026A1/en not_active Abandoned
-
2020
- 2020-04-20 US US16/853,444 patent/US20200248150A1/en not_active Abandoned
-
2021
- 2021-11-09 US US17/522,216 patent/US20220064605A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0416950A8 (pt) | métodos para remover vírus de uma composição do fator vii líquida, para inativar vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquida | |
| ES2240446T3 (es) | Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c. | |
| ATE503764T1 (de) | Inhibitoren des hepatitis-c-virus | |
| ATE481106T1 (de) | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer | |
| NO20044895L (no) | Substituerte cykloalkyl P1' hepatitt C virus inhibitorer | |
| NO20063205L (no) | Inhibitorer for hepatitt C-virus NS3/NS4A-serinprotease | |
| MY140710A (en) | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus | |
| DK0891420T4 (da) | Fremgangsmåde til replikation af influenzavirus i cellekultur samt de ved fremgangsmåden opnåelige influenzavirus | |
| ATE327246T1 (de) | Hepatitis c tripeptid inhibitoren | |
| NO20064356L (no) | Forbindelser som inhibitorer for hepatitt C-virun-NS3-erinprotease | |
| NO20052071L (no) | Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer. | |
| NO20064357L (no) | Nye forbindelser som inhibitorer for hepatitt C-virus-NS3-serinprotease | |
| WO2007008657A3 (en) | Hepatitis c virus inhibitors | |
| UY27614A1 (es) | Formulaciones estabilizadas de adenovirus | |
| EA200900298A1 (ru) | Ингибиторы вируса гепатита с | |
| NO20090438L (no) | Hepatit C virus inhibitorer | |
| WO2006130626A3 (en) | Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period | |
| DK1417228T3 (da) | Peptider der er effektive til behandling af tumorer og andre tilstande som kræver fjernelse eller destruktion af celler | |
| NO20071953L (no) | RNAi modulering av RSV, PIV og andre respiratoriske viruser og anvendelse derav | |
| NZ620988A (en) | Method for purifying recombinant adamts13 and other proteins and compositions thereof | |
| WO2005087731A8 (en) | Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| SG159542A1 (en) | Compositions against sars-coronavirus and uses thereof | |
| NO20064355L (no) | Nye ketoamider med sykliske P4-er som inhibitorer for NS3-serinprotease fra hepatitt C-virus | |
| DK2261377T3 (da) | Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membran-fusogene kappeproteiner | |
| DK1845164T3 (da) | Promoterer til ekspression i modificeret vacciniavirus ankara |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: NOVO NORDISK HEALTH CARE AG (CH) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/05/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25G | Requested change of headquarter approved |
Owner name: NOVO NORDISK HEALTH CARE AG (CH) |